Harvard BioscienceFRA:HBI0 48 Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €13.30. The stock has 6 warning signs investors should review. Among 316 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 316455.38% on this metric.
As of today (2026-06-26), the Forward Annual Dividend Yield of Harvard Bioscience is 0.00%.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Harvard Bioscience is 0.00%.
FRA:HBI0's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.045 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Harvard Bioscience Forward Dividend Yield % Related Terms
FRA:HBI0 vs FEMY, RVP, MLSS: Forward Dividend Yield % Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Harvard Bioscience (FRA:HBI0) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #999999 out of 316 companies in the Medical Devices & Instruments industry.
Is Harvard Bioscience's Forward Dividend Yield % too high?
Harvard Bioscience's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Harvard Bioscience ranks #999999 out of 316 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Forward Dividend Yield % compare to FEMY and RVP?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #999999 out of 316 companies for Forward Dividend Yield %. This places Harvard Bioscience in the lower half of its industry. The industry median Forward Dividend Yield % is 2.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.05, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Forward Dividend Yield % of 0.00%. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.
Key valuation signals for FRA:HBI0:
Forward Dividend Yield %: 0.00%
GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for FRA:HBI0
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 